<?xml version='1.0' encoding='utf-8'?>
<document id="26424199"><sentence text="Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014." /><sentence text="Regulatory approval documents contain valuable information, often not published, to assess the drug-drug interaction (DDI) profile of newly marketed drugs" /><sentence text=" This analysis aimed to systematically review all drug metabolism, transport, pharmacokinetics, and DDI data available in the new drug applications and biologic license applications approved by the U" /><sentence text="S" /><sentence text=" Food and Drug Administration in 2014, using the University of Washington Drug Interaction Database, and to highlight the significant findings" /><sentence text=" Among the 30 new drug applications and 11 biologic license applications reviewed, 35 new molecular entities (NMEs) were well characterized with regard to drug metabolism, transport, and/or organ impairment and were fully analyzed in this review" /><sentence text=" In vitro, a majority of the NMEs were found to be substrates or inhibitors/inducers of at least one drug metabolizing enzyme or transporter" /><sentence text=" In vivo, when NMEs were considered as victim drugs, 16 NMEs had at least one in vivo DDI study with a clinically significant change in exposure (area under the time-plasma concentration curve or Cmax ratio ≥2 or ≤0" /><sentence text="5), with 6 NMEs shown to be sensitive substrates of cytochrome P450 enzymes (area under the time-plasma concentration curve ratio ≥5 when coadministered with potent inhibitors): paritaprevir and naloxegol (CYP3A), eliglustat (CYP2D6), dasabuvir (CYP2C8), and tasimelteon and pirfenidone (CYP1A2)"><entity charOffset="178-190" id="DDI-PubMed.26424199.s9.e0" text="paritaprevir" /><entity charOffset="195-204" id="DDI-PubMed.26424199.s9.e1" text="naloxegol" /><entity charOffset="206-211" id="DDI-PubMed.26424199.s9.e2" text="CYP3A" /><entity charOffset="214-224" id="DDI-PubMed.26424199.s9.e3" text="eliglustat" /><entity charOffset="226-232" id="DDI-PubMed.26424199.s9.e4" text="CYP2D6" /><entity charOffset="235-244" id="DDI-PubMed.26424199.s9.e5" text="dasabuvir" /><entity charOffset="246-252" id="DDI-PubMed.26424199.s9.e6" text="CYP2C8" /><entity charOffset="259-270" id="DDI-PubMed.26424199.s9.e7" text="tasimelteon" /><entity charOffset="275-286" id="DDI-PubMed.26424199.s9.e8" text="pirfenidone" /><entity charOffset="288-294" id="DDI-PubMed.26424199.s9.e9" text="CYP1A2" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e0" e2="DDI-PubMed.26424199.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e0" e2="DDI-PubMed.26424199.s9.e1" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e0" e2="DDI-PubMed.26424199.s9.e2" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e0" e2="DDI-PubMed.26424199.s9.e3" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e0" e2="DDI-PubMed.26424199.s9.e4" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e0" e2="DDI-PubMed.26424199.s9.e5" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e0" e2="DDI-PubMed.26424199.s9.e6" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e0" e2="DDI-PubMed.26424199.s9.e7" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e0" e2="DDI-PubMed.26424199.s9.e8" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e0" e2="DDI-PubMed.26424199.s9.e9" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e1" e2="DDI-PubMed.26424199.s9.e1" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e1" e2="DDI-PubMed.26424199.s9.e2" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e1" e2="DDI-PubMed.26424199.s9.e3" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e1" e2="DDI-PubMed.26424199.s9.e4" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e1" e2="DDI-PubMed.26424199.s9.e5" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e1" e2="DDI-PubMed.26424199.s9.e6" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e1" e2="DDI-PubMed.26424199.s9.e7" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e1" e2="DDI-PubMed.26424199.s9.e8" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e1" e2="DDI-PubMed.26424199.s9.e9" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e2" e2="DDI-PubMed.26424199.s9.e2" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e2" e2="DDI-PubMed.26424199.s9.e3" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e2" e2="DDI-PubMed.26424199.s9.e4" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e2" e2="DDI-PubMed.26424199.s9.e5" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e2" e2="DDI-PubMed.26424199.s9.e6" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e2" e2="DDI-PubMed.26424199.s9.e7" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e2" e2="DDI-PubMed.26424199.s9.e8" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e2" e2="DDI-PubMed.26424199.s9.e9" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e3" e2="DDI-PubMed.26424199.s9.e3" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e3" e2="DDI-PubMed.26424199.s9.e4" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e3" e2="DDI-PubMed.26424199.s9.e5" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e3" e2="DDI-PubMed.26424199.s9.e6" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e3" e2="DDI-PubMed.26424199.s9.e7" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e3" e2="DDI-PubMed.26424199.s9.e8" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e3" e2="DDI-PubMed.26424199.s9.e9" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e4" e2="DDI-PubMed.26424199.s9.e4" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e4" e2="DDI-PubMed.26424199.s9.e5" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e4" e2="DDI-PubMed.26424199.s9.e6" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e4" e2="DDI-PubMed.26424199.s9.e7" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e4" e2="DDI-PubMed.26424199.s9.e8" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e4" e2="DDI-PubMed.26424199.s9.e9" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e5" e2="DDI-PubMed.26424199.s9.e5" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e5" e2="DDI-PubMed.26424199.s9.e6" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e5" e2="DDI-PubMed.26424199.s9.e7" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e5" e2="DDI-PubMed.26424199.s9.e8" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e5" e2="DDI-PubMed.26424199.s9.e9" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e6" e2="DDI-PubMed.26424199.s9.e6" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e6" e2="DDI-PubMed.26424199.s9.e7" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e6" e2="DDI-PubMed.26424199.s9.e8" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e6" e2="DDI-PubMed.26424199.s9.e9" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e7" e2="DDI-PubMed.26424199.s9.e7" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e7" e2="DDI-PubMed.26424199.s9.e8" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e7" e2="DDI-PubMed.26424199.s9.e9" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e8" e2="DDI-PubMed.26424199.s9.e8" /><pair ddi="false" e1="DDI-PubMed.26424199.s9.e8" e2="DDI-PubMed.26424199.s9.e9" /></sentence><sentence text=" As perpetrators, seven NMEs showed clinically significant inhibition involving both enzymes and transporters, although no clinically significant induction was observed" /><sentence text=" Physiologically based pharmacokinetic modeling and pharmacogenetics studies were used for six and four NMEs, respectively, to optimize dosing recommendations in special populations and/or multiple impairment situations" /><sentence text=" In addition, the pharmacokinetic evaluations in patients with hepatic or renal impairment provided useful quantitative information to support drug administration in these fragile populations" /><sentence text=" " /></document>